While we appreciate the authors’ intent to summarize investigations into CGRP pathway–targeted treatments and GI physiology, key methodological information was not described, and limited data were used to make broad conclusive statements linking constipation and the mAb therapies that target the CGRP pathway, including erenumab, fremanezumab, and galcanezumab. This evidence concerns the gene CALCA and constipation disorder.